Key terms
About PRLD
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PRLD news
Mar 13
4:49am ET
Prelude Therapeutics initiated with an Outperform at JMP Securities
Mar 13
12:30am ET
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)
Feb 20
6:08am ET
Prelude Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Feb 17
1:01am ET
New Accounting & Financial Operations Risk for Prelude Therapeutics, Inc. – What’s the Latest?
Feb 16
6:59am ET
Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)
Feb 16
6:02am ET
Prelude Therapeutics files to sell 7.94M shares of common stock for holders
Dec 19
7:09am ET
Prelude Therapeutics downgraded to Underweight at Morgan Stanley
No recent press releases are available for PRLD
PRLD Financials
Key terms
Ad Feedback
PRLD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PRLD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
